Imatinib Teva (Imatinib)

Imatinib Teva is a targeted antineoplastic agent that interferes with specific oncogenic signaling pathways.

• Chronic myeloid leukemia (CML): helps achieve hematologic and cytogenetic remission by suppressing malignant clone proliferation.
• Gastrointestinal stromal tumor (GIST): reduces tumor growth and disease progression in patients with KIT or PDGFRA mutations.
• Philadelphia‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when used in combination regimens.

• Imatinib selectively inhibits the BCR‑ABL tyrosine kinase as well as KIT and PDGFRA receptors. By binding to the ATP‑binding pocket of these enzymes, it blocks downstream phosphorylation events that drive uncontrolled cell division, thereby inducing apoptosis of malignant cells and slowing disease progression.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools.
• Muscle cramps: occasional skeletal discomfort.
• Rash: mild skin irritation.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Myelosuppression: neutropenia, anemia, or thrombocytopenia.
• Cardiotoxicity: congestive heart failure signs.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary hypertension: shortness of breath and elevated pulmonary pressure.
• Renal impairment: increased creatinine or reduced clearance.

Patients and prescribers should consider several safety measures before and during therapy.

• Baseline assessment: obtain complete blood count, liver function tests, and renal function before initiating treatment.
• Monitoring: perform regular hematologic and biochemical labs to detect early toxicity.
• Drug interactions: review concomitant medications for potential CYP3A4 modulators.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks.
• Cardiovascular health: assess cardiac function in patients with pre‑existing heart disease.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Imatinib may alter the pharmacokinetics of several co‑administered agents.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma levels and toxicity risk.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may affect absorption, consider timing adjustments.
• Anticoagulants (e.g., warfarin): monitor INR more frequently.
• Vaccines: live attenuated vaccines should be avoided during therapy.
• Concomitant chemotherapy: assess overlapping toxicities, especially myelosuppression.